Xerostomia Market

DelveInsight’s “Xerostomia– Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the Xerostomia, historical and forecasted epidemiology as well as the Xerostomia market trends in the United States, EU4 (Germany, Spain, Italy, France), and the United Kingdom, and Japan.

 

The Xerostomia market report provides current treatment practices, emerging drugs, Xerostomia market share of the individual therapies, and current and forecasted Xerostomia market size from 2019 to 2032, segmented by seven major markets. The report also covers current Xerostomia treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

 

Geography Covered

• The United States
• EU4 (Germany, France, Italy, Spain), and the United Kingdom
• Japan

 

Study period: 2019–2032

 

Xerostomia Understanding and Treatment Algorithm

The DelveInsight’s Xerostomia market report gives a thorough understanding of Xerostomia by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment. 

 

Xerostomia is defined as the “complaint of oral dryness”. It can occur due to inadequate salivary secretion secondary to abnormal function of the salivary glands, which is categorized as “true” xerostomia; however, most patients with xerostomia often do not have objective signs of hyposalivation. “Symptomatic” xerostomia or “pseudo” xerostomia refers to oral dryness despite normal salivary gland function. 

 

Xerostomia diagnosis

The diagnosis of xerostomia begins with taking a thorough medical history. A review of the patient’s medications, medical history, including head and neck radiation, and social history are all needed to determine the underlying causes of dry mouth. Salivary flow rates can also be counted for an objective diagnosis of hyposalivation. A diagnosis of salivary gland dysfunction can also be made with imaging including sialography, scintigraphy with technetium-99m, and computed tomography scan or magnetic resonance imaging of the salivary glands. 

 

Xerostomia treatment

Topical medications are the first-line treatments recommended for xerostomia. Salivary stimulants and substitutes, including toothpaste, mouthwashes, and gels, can improve salivary gland function. Saliva substitutes resemble natural saliva and increase salivary viscosity.91 Saliva substitutes commonly contain carboxymethylcellulose, xanthan gum, mucins, hydroxyethylcellulose, polyethylene oxide, or linseed oil.

 

Sprays have also been used for the treatment of xerostomia. A sialogogue spray, composed of 1% malic acid, has produced benefits in antihypertensive- and antidepressant-induced xerostomia, but it has a potential risk for enamel loss. Mucin sprays, tablets, and lozenges may be used in reducing the findings in dry mouth. Hyperbaric oxygen for patients who have undergone radiation has been reported to increase salivary function. 

 

Xerostomia Epidemiology

The Xerostomia epidemiology section provides insights into the historical and current Xerostomia patient pool and forecasted trends for seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Xerostomia report also provides the diagnosed patient pool, their trends, and assumptions undertaken.

 

Key findings

According to the European Association of Oral Medicines (2022), Xerostomia is the subjective complaint of oral dryness and is medically classified as a symptom. It is especially frequent in the elderly and has been reported to occur in 17 to 39% of persons aged 65 years or more. In addition, xerostomia is more frequent among women than men.

 

According to the results published by Rech et al. (2019), the prevalence of xerostomia, of low stimulated salivary flow rate and low at rest salivary flow rate were 38.8%, 56.6%, and 36.7%, respectively. An important portion of the sample concurrently presented xerostomia and salivary hypofunction in 22.4% of patients. The sample included patients with an average age of 68.5 ± 6.7 years, and the majority of the patients in the sample were women (65.3%).

 

In a study by Villa et al. (2011), the overall prevalence of xerostomia in participants was 7% in Italy.

 

The Xerostomia epidemiology covered in the report provides historical as well as forecasted Xerostomia epidemiology [segmented as Total prevalent cases of Xerostomia, Gender-specific prevalence of Xerostomia, Age-specific prevalence of Xerostomia, and Diagnosed and Treated Cases of Xerostomia] in the 7MM covering the United States, EU4 (Germany, France, Italy, Spain), and the United Kingdom, and Japan from 2019 to 2032.

 

Country-wise Xerostomia Epidemiology

The epidemiology segment also provides the Xerostomia epidemiology data and findings across the United States, EU4 (Germany, France, Italy, Spain), and the United Kingdom, and Japan.

Xerostomia Recent Developments

• In December 2024, MeiraGTx (MGTX) announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to AAV2-hAQP1 for treating Grade 2/3 radiation-induced xerostomia (RIX).

Xerostomia Drug Chapters

The drug chapter segment of the Xerostomia report encloses the detailed analysis of Xerostomia marketed drugs and late-stage (Phase III and Phase II) Xerostomia pipeline drugs. It also helps understand the Xerostomia clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

 

Marketed Xerostomia drugs

Pilocarpine and Cevimeline

The two systemic agents that are approved therapies for xerostomia by the US Food and Drug Administration are oral pilocarpine and cevimeline. Pilocarpine is a nonselective muscarinic agonist and parasympathetic agent. The recommended starting dose is 5 mg for a maximum of 30 mg daily. Pilocarpine specifically can diminish dry mouth in patients who have undergone radiation therapy to the head and neck. 

 

Cevimeline is a muscarinic agonist that is selective for M1 and M3 receptors, which are located in the lacrimal and salivary glands. It has fewer side effects than pilocarpine because it does not affect M2 receptors. Standard dosing is 30 mg three times daily for at least 3 months.

 

Note: Detailed Current therapies assessment will be provided in the full report

 

Emerging Xerostomia drugs

AAV2hAQP1- MeiraGTx

AAV2hAQP1 is being developed to treat radiation-induced xerostomia (RIX) by increasing water conduction in the salivary glands damaged by radiation therapy. This gene therapy product candidate works by introducing a water conducting channel into the remaining epithelial cells of these damaged glands. Recently, in December 2021, MeiraGTx announced Positive Preliminary Data from the AQUAx Phase I Clinical Trial of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia. These results point to the potential for AAV-hAQP1 to be a disease-modifying one-time treatment for this large population of patients who currently have no effective treatment options for this devastating and intractable condition. 

 

LBS-020- Lubris Biopharma

LBS-020 being developed by Lubris Pharma is a recombinant lubricin and a glycoprotein stimulant. Lubricin is a large endogenous complex glycoprotein that binds to and protects tissue surfaces from friction. LBS-020 is still in the preclinical phase.

 

Note: Detailed emerging therapies assessment will be provided in the full report

 

Xerostomia Market Outlook

Currently, the market for xerostomia treatment includes a variety of products, including saliva substitutes, oral moisturizers, and prescription medications. Saliva substitutes, which are designed to mimic the properties of natural saliva, are the most widely used products for xerostomia treatment. 

 

According to DelveInsight, the Xerostomia market in 7MM is expected to witness a major change in the study period 2019–2032 as the prevalence of the condition is expected to increase due to aging populations, rising incidence of chronic diseases, and increased use of medications that cause dry mouth as a side effect.

 

Key findings

This section includes a glimpse of the Xerostomia market in 7MM.

 

The United States: Xerostomia Market Outlook

This section provides the total Xerostomia market size and market size by therapies in the United States.

 

EU4 and the UK Countries: Xerostomia Market Outlook

The total Xerostomia market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

 

Japan: Xerostomia Market Outlook

The total Xerostomia market size and market size by therapies in Japan are also mentioned.

 

Xerostomia Drug Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Xerostomia market or expected to get launched in the market during the study period 2019–2032. The analysis covers Xerostomia market uptake by drugs, patient uptake by therapies, and sales of each drug.

 

This will help in understanding the Xerostomia drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

 

Xerostomia Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyzes Xerostomia’s key players involved in developing targeted therapeutics.

 

Xerostomia market clinical trial development activities

The report covers detailed information on collaborations, acquisitions, and mergers, licensing patent details, and other information for Xerostomia emerging therapies.

 

Xerostomia Reimbursement Scenario

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

 

KOL Views

To keep up with current epidemiology and market trends, we take KOLs and SMEs' opinions working in the Xerostomia domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies and treatment patterns along with Xerostomia market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

 

Competitive Intelligence Analysis

We perform competitive and market intelligence analysis of the Xerostomia market by using various competitive intelligence tools that include – SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

 

Scope of the Report

• Descriptive overview of Xerostomia, disease overview, patient journeys, treatment algorithms, diagnosis, and currently available therapies
• Comprehensive insight into the Xerostomia epidemiology and forecasts in the 7MM
• An all-inclusive account of both the current and emerging therapies for Xerostomia, along with the assessment of new therapies, expected to have an impact on the current treatment landscape
• Exhaustive analysis of the Xerostomia market; historical and forecasted covering drug outreach in the 7MM
• Detailed patient-based market forecasting determines the trends shaping and driving the global Xerostomia market

 

Report Highlights

• In the coming years, the Xerostomia market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Xerostomia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing Xerostomia therapies. The launch of emerging therapies will significantly impact the Xerostomia market
• A better understanding of Xerostomia pathogenesis will also contribute to the development of novel therapeutics for Xerostomia
• Our in-depth analysis of the Xerostomia pipeline assets across different stages of development (Phase III and Phase II), emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

 

Xerostomia Report Insights

• Patient-Based Market Forecasting 
• Therapeutic approaches
• Xerostomia pipeline analysis
• Xerostomia market size and trends
• Xerostomia market opportunities
• Impact of upcoming therapies

 

Xerostomia Report Key Strengths

• 10 years forecast
• 7MM Coverage
• Xerostomia epidemiology segmentation
• Key cross competition
• KOL views
• Xerostomia drugs uptake

 

Xerostomia Report Assessment

• Current treatment practices
• Unmet needs
• Xerostomia pipeline product profiles
• Xerostomia market attractiveness

 

Key Questions

Xerostomia market insights:

• What would be the Xerostomia market growth till 2032, and what will be the resultant market size in 2032?
• What was the Xerostomia drug class share (in percentage) distribution in 2019, and how would it look in 2032?
• What would be the Xerostomia total market size and market size by therapies across the 7MM during the forecast period (2023–2032)?
• What are the key findings of the market across 7MM, and which country will have the largest Xerostomia market size during the forecast period (2023–2032)
• How would the unmet needs affect the Xerostomia market dynamics and subsequent analysis of the associated trends?

 

Xerostomia Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of Xerostomia?
• What is the historical and forecasted Xerostomia patient pool in 7MM, and where can one observe the highest patient population and growth opportunities? 
• What are the key factors driving the epidemiology trends for seven major markets covering the United States, EU4 (Germany, Spain, France, Italy), and the UK, and Japan?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

• What are the current treatment guidelines and treatment options, in addition to approved therapies for Xerostomia in the US, Europe, and Japan?
• What are the key collaborations (Industry–Industry, Industry-Academia), mergers and acquisitions, and licensing activities related to Xerostomia therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Xerostomia and its status, along with the challenges faced?

 

Reasons to Buy

• The patient-based market forecast analysis will help in developing business strategies by understanding trends shaping and driving the Xerostomia market
• Organize sales and marketing efforts by identifying the best opportunities for Xerostomia in the US, EU4 (Germany, Spain, Italy, France), and the United Kingdom, and Japan
• Identification of strong upcoming players in the market that will help devise strategies that will help in getting ahead of competitors